All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
Bookmark this article
Lova Sun of Massachusetts General Hospital, and colleagues, published results of 16 years of retrospective chart review for outcomes of autologous stem cell transplant (ASCT) in patients over 70 years old. The review was published in the online edition of The Oncologist December 28, 2017.
ASCT is the standard treatment for chemotherapy-sensitive relapsed lymphoma patients. Medical practitioners may be hesitant to offer transplant to older patients due to concerns for higher risk for poor outcomes due to infections, organ toxicities or non-relapse mortality (NRM). The purpose of this review was to observe safety outcomes over an extended period and determine if any clinical factors influence favorable versus poor outcomes in elderly lymphoma patients.
This study demonstrated that elderly patients are still viable candidates for ASCT, with good clinical outcomes and acceptable expected toxicities. Survival status has improved in recent years, which likely reflects improvements in supportive care, toxicity management and infection prophylaxis. The authors recommended that elderly lymphoma patients should be selected based on individual patient characteristics for ASCT and not excluded as candidates based on age alone.
Understanding your specialty helps us to deliver the most relevant and engaging content.
Please spare a moment to share yours.
Please select or type your specialty
Your opinion matters
Chemo-free combination of lenalidomide + rituximab in elderly/frail patients with MCL and DLBCL
Mantle cell lymphoma (MCL) is acknowledged as an incurable disease with no international standard of care for elderly patients who are unfit for high-dose...
Results from a phase II study: brentuximab plus DTIC is a good choice in elderly, front-line HL patients
The results of this study ought to serve as a template and give rise to additional studies of novel induction regimens for elderly HL patients.
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox